NASDAQ: TILInstil Bio Inc Stock
$19.00+0.49 (+2.65%)
Updated Oct 23, 2025
TIL Price
$19.00
Fair Value Price
-$11.99
Market Cap
$128.26M
52 Week Low
$10.80
52 Week High
$44.50
P/E
-1.47x
P/B
0.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$84.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.75
Operating Cash Flow
-$50M
Beta
1.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TIL Overview
Instil Bio Incorporated is a biopharmaceutical company developing cancer therapies. Its Tumor Infiltrating Lymphocyte (TIL) product candidates in pipeline include ITIL-168 for as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer, and ITIL-306 for gynecological, non-small cell lung cancer, renal caner, and others. Imstil Bio was incorporated in 2018 and is headquartered in Dallas, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TIL's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TIL
Ranked#433 of 486
Ranked#433 of 486
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.14 | A | |
| $11.58 | A | |
| $7.19 | A |
Be the first to know about important TIL news, forecast changes, insider trades & much more!
TIL News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TIL ($19.00) is overvalued by 258.42% relative to our estimate of its Fair Value price of -$11.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TIL ($19.00) is not significantly undervalued (258.42%) relative to our estimate of its Fair Value price of -$11.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TIL due diligence checks available for Premium users.
Valuation
TIL fair value
Fair Value of TIL stock based on Discounted Cash Flow (DCF)
Price
$19.00
Fair Value
-$11.99
Undervalued by
258.42%
TIL ($19.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TIL ($19.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.47x
Industry
-87.14x
Market
38.83x
TIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
4.91x
TIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TIL's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.4M
Profit Margin
0%
TIL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$231.0M
Liabilities
$99.3M
Debt to equity
0.75
TIL's short-term assets ($207.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TIL's short-term assets ($207.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.8M
Investing
-$400.0k
Financing
$6.7M
TIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TIL vs Biotech Stocks
Instil Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.